| Literature DB >> 25399966 |
Maziar Mohaddes1, Ola Rolfson, Johan Kärrholm.
Abstract
BACKGROUND ANDEntities:
Mesh:
Substances:
Year: 2014 PMID: 25399966 PMCID: PMC4366676 DOI: 10.3109/17453674.2014.984114
Source DB: PubMed Journal: Acta Orthop ISSN: 1745-3674 Impact factor: 3.717
Figure 1.Distribution of different cup designs, used at first-time cup revisions, reported to the SHAR in the period 2006–2012. The proportion of TM and other uncemented cups increased during these 7 years.
Demography of patients operated during the period 2006–2012 with Trilogy, TM, or Lubinus designs, reported to the Swedish Hip Arthroplasty Register
| Demographic | Trilogy | TM | Lubinus |
|---|---|---|---|
| Total number of revisions | 870 | 805 | 785 |
| Sex | |||
| Female | 57% | 52% | 54% |
| Primary diagnosis | |||
| Osteoarthritis | 78% | 73% | 78% |
| Fixation method—primary cup | |||
| Cemented | 82% | 78% | 85% |
| Concomitant stem revision | 48% | 53% | 58% |
| Bone grafting used at | |||
| index revision | 60% | 45% | 58% |
| Mean age at index | |||
| revision, years (range) | 72 (29–93) | 70 (19–94) | 73 (39–95) |
| Mean follow-up, years (range) | 3.6 (0–7) | 2.6 (0–7) | 3.7 (0–7) |
TM: trabecular metal.
Figure 2.5-year crude cumulative survival probability with reoperation as endpoint for Trilogy, TM, and Lubinus designs used in first-time cup revision.
Figure 3.5-year crude cumulative survival probability with re-revision as endpoint for Trilogy, TM, and Lubinus designs used in first-time cup revision.
Risk factors for reoperation and re-revision; comparison between the 3 most frequently used designs in the Swedish Hip Arthroplasty Register (Cox regression analysis)
| Risk factor | Reoperation | Re-revision | ||||
|---|---|---|---|---|---|---|
| RR | 95% CI | p-value | RR | 95% CI | p-value | |
| Sex | ||||||
| Male | 1.1 | 0.83–1.4 | 0.6 | 1.1 | 0.76–1.5 | 0.7 |
| Female | 1 | 1 | ||||
| Age, years | ||||||
| < 70 | 1.1 | 0.79–1.5 | 0.6 | 1.3 | 0.84–1.9 | 0.3 |
| 70–79 | 1 | 1 | ||||
| > 79 | 0.87 | 0.59–1.3 | 0.5 | 1.1 | 0.64–1.7 | 0.8 |
| Primary diagnosis | ||||||
| Secondary OA | 1.2 | 0.88–1.7 | 0.3 | 1.4 | 0.96–2.1 | 0.08 |
| Primary OA | 1 | 1 | ||||
| Primary cup | ||||||
| Uncemented | 0.98 | 0.68–1.4 | 0.9 | 1.1 | 0.73–1.8 | 0.6 |
| Cemented | 1 | 1 | ||||
| Acetabular bone | ||||||
| grafting | ||||||
| Yes | 0.91 | 0.68–1.2 | 0.5 | 0.9 | 0.64–1.3 | 0.7 |
| No | 1 | 1 | ||||
| Components revised | ||||||
| Cup | 1.1 | 0.85–1.5 | 0.4 | 1.8 | 1.23–2.6 | 0.002 |
| Cup + stem | 1 | 1 | ||||
| Cup | ||||||
| TM | 0.85 | 0.61–1.2 | 0.3 | 0.8 | 0.54–1.2 | 0.3 |
| Lubinus | 0.78 | 0.57–1.1 | 0.1 | 0.6 | 0.41–0.97 | 0.04 |
| Trilogy | 1 | 1 | ||||
RR: risk ratio; CI: 95% confidence interval.
Reference.
Inflammatory hip desease (8%), sequelae after childhood disease (6%), fracture (4%), avascular necrosis (3%), and other (2%).
Primary ostheoarthritis (77%).
Cup used at index revision.
Trabecular metal.
Publications in revision surgery using porous tantalum cups
| Reoperation due to | ||||||
|---|---|---|---|---|---|---|
| Study | No. of hips | Age (range) | Follow-up, years (range) | aseptic loosening | dislocation | infection |
| 60 | 64 (28–75) | 3.5 (1–6) | 2% | 12% | 0% | |
| 13 | 63 (47–88) | 2.6 (1–3) | 0% | 0% | 0% | |
| 23 | 58 (34–84) | 3 (2–4) | 0% | 4% | 0% | |
| 53 | 63 (29–86) | 4 (2–6) | 4% | 6% | 0% | |
| 34 | 64 (37–97) | 3 (2–5) | 6% | 3% | 0% | |
| Van | 97 | 59 (27–87) | 3.8 (2–7) | 0% | 1% | 8% |
| 46 | 67 (39–85) | 4.2 (2–6) | 0% | 0% | 2% | |
| 827 | 69 (16–94) | 1.1 (0–3) | 1% | 3% | 0.2% | |
Indications for reoperation and re-revision in different groups
| Reason for a second intervention | Reoperation | Re-revision | ||||
|---|---|---|---|---|---|---|
| Trilogy | TM | Lubinus | Trilogy | TM | Lubinus | |
| Aseptic loosening | 13 (1.5) | 10 (1.2) | 16 (2.0) | 10 (1.1) | 8 (1.0) | 11 (1.4) |
| Infection | 28 (3.2) | 11 (1.4) | 13 (1.7) | 23 (2.6) | 5 (0.6) | 7 (0.9) |
| Fracture | 15 (1.7) | 8 (1.0) | 11 (1.4) | 2 (0.2) | 1 (0.1) | 5 (0.6) |
| Dislocation | 20 (2.3) | 25 (3.1) | 17 (2.2) | 19 (2.2) | 21 (2.6) | 8 (1.0) |
| Other | 14 (1.6) | 8 (1.0) | 6 (0.8) | 7 (0.8) | 3 (0.4) | 2 (0.3) |
| Total | 90 (10.3) | 62 (7.7) | 63 (8.0) | 61 (7.0) | 38 (4.7) | 33 (4.2) |
Data are given as n (%) reoperated or re-revised during the follow-up.